Epitalon
⚠️ Structural Separation Notice
The Ageless Pep Academy is a clinical education property independent from any commerce operation. Any references in this profile to Ageless Peps product SKUs, pricing, or the agelesspeps.com domain are for completeness and transparency; they are not endorsements and do not form part of the clinical education content. Clinicians are responsible for independent verification of any product sourcing decision. The Academy's Medical Director provides editorial oversight only and does not endorse commercial products.
Synthetic pineal tetrapeptide (AEDG) that activates telomerase and restores melatonin production, positioning it as a foundational anti-aging and circadian-repair compound.
Quick Facts
| Property | Value |
|---|---|
| Also Known As | Epithalon, Epithalone, Epithalamin (synthetic analog), AEDG peptide |
| Category | Anti-Aging / Mitochondrial / Sleep |
| Sequence | Ala-Glu-Asp-Gly (AEDG) |
| Molecular Weight | ~390.35 Da |
| Molecular Formula | C14H22N4O9 |
| PubChem CID | 219042 |
| Administration | SubQ / IV / Oral (capsule) |
| Typical Dose Range | 5-10 mg/day SubQ for 10-20 days; 3 mg daily oral (capsule) |
| Half-Life | Very short (minutes) — exhibits "hit and run" epigenetic pharmacology |
| Storage | Lyophilized: -20 C up to 3 years, 2-8 C up to 2 years. Reconstituted: 2-8 C max 2 weeks; protect from UV light. |
| FDA Status | Research-only; not FDA-approved. Parent compound Epithalamin has Russian regulatory history. |
| WADA Status | Prohibited (listed under S0 — Non-Approved Substances) |
Mechanism of Action
Epitalon is a synthetic tetrapeptide designed to replicate the activity of Epithalamin, a polypeptide extract from the bovine pineal gland first characterized by Vladimir Khavinson. Its primary mechanism centers on telomerase activation: Epitalon induces expression of the human telomerase reverse transcriptase (hTERT) gene, the catalytic subunit of telomerase, leading to elongation of telomeres in somatic cells. In vitro, Epitalon-treated human fetal fibroblasts surpassed the Hayflick limit, completing 44+ population doublings versus 34 in controls, with telomeres lengthening by approximately 33% (PMID-12937682, PMID-40908429).
A second major axis of activity involves pineal gland and melatonin restoration. In aged non-human primates, Epitalon administration restored nighttime melatonin peak amplitude approximately 3-fold toward youthful levels, correcting the age-related decline in circadian melatonin secretion (PMID-12096440). This chronobiotic effect is mediated through upregulation of the AANAT/pCREB signaling pathway in pinealocytes.
Epitalon also demonstrates epigenetic modulation — it interacts with specific histone proteins to loosen heterochromatin structure, restoring more youthful gene expression patterns. This includes activation of NRF2-driven antioxidant defense transcription. Additionally, Epitalon exhibits a paradoxical oncological profile: while it activates telomerase in normal somatic cells, preclinical data suggests it may suppress malignant cell growth via immune modulation and H19 gene-mediated pathways (PMID-16634527, PMID-12049808).
Despite its very short plasma half-life (minutes), Epitalon's effects are long-lasting due to its epigenetic mechanism — brief exposure initiates sustained changes in gene expression that persist well beyond the compound's clearance.
Key Research Areas
- Telomerase activation and telomere elongation — The most studied mechanism. Epitalon reactivates hTERT in somatic cells, extending telomere length and cellular lifespan in fibroblast cultures (PMID-12937682, PMID-15455129, PMID-40908429).
- Lifespan extension — In Drosophila melanogaster models, Epitalon extended median lifespan by 11-16% (PMID-11087911).
- Pineal gland and melatonin restoration — Restored circadian melatonin rhythms in aged primates to near-youthful amplitude (PMID-12096440).
- Anti-tumor effects — Reduced spontaneous tumor incidence in rodent models and modulated immune surveillance pathways (PMID-16634527, PMID-12049808).
- Reproductive biology — Independent validation of telomerase activation in bovine oocyte maturation, improving post-thaw embryo development (PMID-35413689, PMID-39788414).
- Comprehensive review — Recent overviews synthesize the totality of Epitalon research across aging, immunity, and neuroprotection (PMID-40141333).
CRITICAL METHODOLOGICAL NOTE: Greater than 90% of published Epitalon research originates from a single research group (Khavinson and colleagues, St. Petersburg Institute of Bioregulation and Gerontology). Only 2 studies represent partially or fully independent replication: Kossoy et al. from Israel (PMID-16634527) and Yue et al. from China (PMID-35413689). This single-group concentration significantly limits confidence in the evidence base. Independent replication from Western laboratories is urgently needed.
Evidence Level Summary
| Evidence Type | Count | Notes |
|---|---|---|
| Human RCTs | 0 | No human trials have been conducted |
| Human observational | 0 | No formal human observational studies |
| Animal in vivo | 3 | Drosophila lifespan, primate melatonin, rodent tumor models |
| In vitro | 3 | Fibroblast telomerase activation, telomere elongation, oocyte maturation |
| Systematic reviews | 0 | None available |
| Narrative reviews | 5 | Primarily from Khavinson group; recent comprehensive overview (PMID-40141333) |
All evidence is Level V (Oxford CEBM). There are zero human clinical trials. Practitioners should communicate this evidence limitation clearly to patients.
Clinical Applications
- Anti-Aging — Primary application; telomerase activation and epigenetic rejuvenation
- Sleep Disorders — Circadian melatonin restoration in age-related sleep disruption
- Cancer Adjunct Therapy — Paradoxical anti-tumor properties (context-dependent; see Contraindications)
Protocols Using This Peptide
Ageless Peps Products
- AP-Epitalon-Vial — EPITALON Vial, variable dosing, $37-$117
Dosing Reference
Research Dosing Ranges (from literature)
| Route | Dose Range | Frequency | Duration | Source |
|---|---|---|---|---|
| SubQ | 5-10 mg/day | Daily | 10-20 days, 1-2x/year | Khavinson protocols; 50-100 mg cumulative per cycle |
| IV | 5-10 mg/day | Daily | 10-20 days | Clinical integrative practice |
| Oral (capsule) | 3 mg/day | Daily | Ongoing or cycled | Capsule formulation |
Cycling
Standard protocol: 10-20 day intensive cycles administered 1-2 times per year, with cumulative dose target of 50-100 mg per cycle. Administer exclusively at nighttime to support the circadian melatonin surge. The "hit and run" pharmacology means that short exposure windows produce sustained epigenetic changes, making intensive short cycles rational despite the very short half-life. Extended low-dose protocols (5 mg/day for 10-20 days, 2x/year) are also used.
Contraindications & Safety
- Contraindications: Active malignancy is context-dependent — Epitalon has anti-tumor preclinical data, but telomerase activation in cancer cells is a theoretical concern. Err on the side of contraindication until human data is available.
- Common side effects: Mild transient fatigue, headaches (self-limiting). Generally well-tolerated in preclinical data.
- Drug interactions: No formal drug interaction studies. Theoretical interaction with exogenous melatonin supplementation (additive chronobiotic effects).
- Pregnancy/nursing: Absolute contraindication — no reproductive safety data in humans.
- Special populations: No pediatric use. Geriatric populations are the primary intended demographic but no human safety trials exist. No renal or hepatic adjustment data.
Safety caveat: There are ZERO human safety trials for Epitalon. The 15-year human follow-up data referenced in some practitioner literature pertains to the parent compound Epithalamin (pineal extract), not the synthetic tetrapeptide Epitalon specifically.
Synergistic Combinations
- MOTS-C + Thymosin Alpha-1 + Epitalon — Comprehensive longevity stack targeting telomeres (Epitalon), mitochondria (MOTS-C), and immune function (TA-1)
- GHK-Cu + Epitalon — Anti-aging synergy; GHK-Cu targets ECM remodeling and gene expression, Epitalon targets telomere maintenance
- BPC-157 + TB-500 + Epitalon — Healing + longevity combination
- NAD+ + Epitalon — Sirtuin/NAD+ axis paired with telomerase activation for multi-pathway aging intervention
- SS-31 + Epitalon — Mitochondrial repair (SS-31) combined with nuclear aging reversal (Epitalon)
Related Research
| PMID | Title | Year | Study Type |
|---|---|---|---|
| PMID-11087911 – Effect of epithalon on the lifespan increase in Drosophila me | Effect of Epithalon on lifespan increase in Drosophila melanogaster | 2000 | Animal in vivo |
| PMID-12049808 – Effect of peptide bioregulators on carcinogenesis | Effect of peptide bioregulators on carcinogenesis | 2002 | Animal in vivo |
| PMID-12096440 – Epitalon restores melatonin production in aged primates | Epitalon restores melatonin production in aged primates | 2003 | Animal in vivo |
| PMID-12937682 – Epithalon peptide induces telomerase activity and telomere e | Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells | 2003 | In vitro |
| PMID-15455129 – Telomerase activation by peptides and telomere elongation | Telomerase activation by peptides and telomere elongation | 2004 | In vitro |
| PMID-16634527 – Epitalon and tumor development in rodent models | Epitalon and tumor development (Kossoy/Israel — independent) | 2006 | Animal in vivo |
| PMID-35413689 – Epitalon-activated telomerase enhance bovine oocyte maturati | Epitalon-activated telomerase enhances bovine oocyte maturation (Yue/China — independent) | 2022 | In vitro |
| PMID-39788414 – Epitalon-activated telomerase enhance bovine oocyte maturati | Epitalon-activated telomerase enhances bovine oocyte maturation and post-thawed embryo development | 2024 | In vitro |
| PMID-40141333 – Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide wi | Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties | 2025 | Narrative review |
| PMID-40908429 – Epitalon increases telomere length in human cell lines throu | Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity | 2025 | In vitro |
| PMID-41240216 – Correction Epitalon increases telomere length in human cell | Correction: Epitalon increases telomere length in human cell lines | 2025 | Correction/Erratum |
References
- PMID-11087911 — Drosophila lifespan extension
- PMID-12049808 — Carcinogenesis bioregulation
- PMID-12096440 — Primate melatonin restoration
- PMID-12937682 — Telomerase activation in human cells
- PMID-15455129 — Telomere elongation
- PMID-16634527 — Anti-tumor effects (independent replication)
- PMID-35413689 — Bovine oocyte maturation (independent replication)
- PMID-39788414 — Oocyte/embryo development
- PMID-40141333 — Comprehensive review
- PMID-40908429 — Telomere length in cell lines
- PMID-41240216 — Correction to above
Research Purposes Only. This vault is for educational and research reference. Nothing constitutes medical advice. Peptide therapies vary in regulatory status by jurisdiction. Always consult a qualified healthcare provider before initiating any peptide protocol. Dosing information reflects ranges reported in peer-reviewed literature and practitioner guides and must be individualized by a clinician.
FDA Disclaimer: The products and claims made about specific products have not been evaluated by the United States Food and Drug Administration and are not approved to diagnose, treat, cure, or prevent disease.
Related
#peptide #anti-aging #sleep #mitochondrial #subq #iv #oral